The Halo Research Platform is for basic research scientists in academia and other research institutions. The Halo Stem and Progenitor Cell, Quality Control (SPC-QC) and Halo-96 PQR (Potency, Quality Release) Platforms were designed for stem cell transplantation and cord blood bank processing laboratories to address the requirement for appropriate and validated assays for umbilical cord blood stem cell products prior to transplantation into patients.
Ivan Rich, founder and CEO of HemoGenix, said: “For a small, but growing company like HemoGenix, IP is of fundamental importance to us, not only as validation for what we do, but also for future business, market share and strategic partnerships.”